ArticleNucleic acids research2002
GATA-4 interacts distinctively with negative and positive regulatory elements in the Fgf-3 promoter.
Article in Nucleic acids research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- The role of GATA4 in mesenchymal stem cell senescence: A new frontier in regenerative medicine.Regenerative therapy · 2025Review
- The sense behind retroviral anti-sense transcription.Virology journal · 2017Article
- Review
- Down-regulation of SM22/transgelin gene expression during H9c2 cells differentiation.Molecular and cellular biochemistry · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GATA-4 binds two sites in the Fgf-3 promoter, PS4A and PS13, which function as positive and negative regulatory elements, respectively. In spite of their opposite functions, both PS4A and PS13 acted as potent enhancer elements when three copies of each were appended to a minimal tk promoter. Mutational analysis showed that the negative regulatory activity of PS13 was dependent on its close proximity to the major transcription initiation site (P3), since it was a stronger repressor when moved closer to P3, but had no significant activity when moved to more distal positions. While only the C-terminal zinc finger and the basic domain of GATA-4 were required for binding to PS13, this was insufficient for binding at PS4A. In addition to the PS4A GATA site, the presence of sequences located 10-12 bp distant was required for efficient binding. Both the sequence and location of this second site was crucial for binding and enhancer activity. Truncation deletions of GATA-4 showed that efficient binding to PS4A was dependent on both zinc fingers and the basic domain, suggesting a direct interaction between one zinc finger domain and a possible second site (AGACAA) that shows some similarity to a GATA motif. GATA-4 binding to PS4A through both zinc finger domains was essential for Fgf-3 promoter activity. The substitution in PS4A of a GATA-binding sequence similar to PS13, which only requires a single zinc finger domain, bound GATA-4 efficiently but did not activate the Fgf-3 promoter. These differences in GATA-4 binding were also reflected in DNA bending assays that suggested clear conformational differences between complexes formed on PS4A and PS13.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.